anticoagulant/neoplasms

TECHNICAL FIELD The present invention relates to compositions and associated methods for suppression of primary tumor growth and metastasis by use of sulfated, super-sulfated non-anticoagulant low and ultra-low molecular weight heparins, and their nanoformulations. BACKGROUND The Glycosaminoglycans

BACKGROUND OF THE INVENTION The present invention relates to glycosaminoglycan derivatives useful in the inhibition of endoglycosidase activity and of tumor invasiveness or metastatic spread. A class of biological substances called the proteoglycans form the ground substance in the extracellular

FIELD OF THE INVENTION This invention relates to the prevention and treatment of tumor growth, metastasis, and cancer associated thromboembolic disorders, and more particularly to such treatment by the administration of a lyophilized formulation of an antiplatelet such as the platelet GPIIb/IIIa

FIELD OF THE INVENTION The teachings herein relate to devices and methods for stabilizing and preserving circulating tumor cells without damaging the tumor cell integrity for improved protection and regulation of circulating tumor cells during collection, storage, and shipment. BACKGROUND OF THE

FIELD OF THE INVENTION The teachings herein relate to devices and methods for stabilizing and preserving circulating tumor cells without damaging the tumor cell integrity for improved protection and regulation of circulating tumor cells during collection, storage, and shipment. BACKGROUND OF THE

FIELD OF THE INVENTION The present invention relates to new protein analogues of the Extrinsic Pathway Inhibitor (EPI; also known as Tissue Factor Pathway Inhibitor, TFPI, or Lipoprotein-Associated Pathway Inhibitor, LACI). The invention also features a method of making the analogues and therapeutic

BACKGROUND OF THE INVENTION Field of the Invention This invention is an extension of Applicants' prior invention disclosed in the above-referenced patent applications relating to novel anti-IL-6 antibodies, novel therapies and therapeutic protocols utilizing anti-IL-6 antibodies, and pharmaceutical

The sequence listing in the file named "56256o2006.txt" having a size of 332,224 bytes that was created Sep. 26, 2017 is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Field of the Invention This invention is an extension of Applicants' prior invention disclosed in the

BACKGROUND OF THE INVENTION The present invention relates to therapeutic uses of bactericidal/permeability increasing (BPI) protein products for the treatment of conditions related to gram-negative bacterial infection and the conditions not directly associated with gram-negative bacterial infection,

BACKGROUND OF THE INVETION The present invention relates to therapeutic uses of bactericidal/permeability increasing (BPI) protein products for the treatment of conditions related to gram-negative bacterial infection and the conditions not directly associated with gram-negative bacterial infection,

BACKGROUND OF THE INVENTION The present invention relates to therapeutic uses of bactericidal/permeability increasing (BPI) protein products for the treatment of conditions related to gram-negative bacterial infection and the conditions not directly associated with gram-negative bacterial infection,

BACKGROUND OF THE INVENTION The present invention relates to therapeutic uses of bactericidal/permeability increasing (BPI) protein products for the treatment of conditions not directly associated with gram negative bacterial infection including neutralization of the anti-coagulant properties of

TECHNICAL FIELD The present invention relates to: a method for growing, rapidly and massively ex vivo, cells collected from a living subject; cells grown by the method; a pharmaceutical preparation for biological tissue repair and regeneration comprising the cells; and a method for producing the

CROSS-REFERENCE TO RELATED APPLICATION This application is the U.S. National Stage of PCT International Application PCT/J P2008/002503, filed Sep. 10, 2008, and claims the benefit of foreign priority under 35 U.S.C. .sctn.119 based on JP Appln No. 2007-235436, filed Sep. 11, 2007, JP Appln. No.

FIELD OF THE INVENTION The invention relates to rationally designed polysaccharide lyases and uses thereof. In particular, the invention relates to modified chondroitinase B. The modified chondroitinase B enzymes of the invention are useful for a variety of purposes, including cleaving and